Carol Levy, Ryan Bailey, Lori Mb Laffel, Gregory P Forlenza, Linda A DiMeglio, Michael S Hughes, Sue Brown, Grazia Aleppo, Anuj Bhargava, Viral Shah, Mark A Clements, Mark S Kipnes, Brittany Bruggeman, Mark Daniels, Henry Rodriguez, Peter Calhoun, John Lum, Ravid Sasson-Katchalski, Jordan E Pinsker, Robyn Pollom, Roy W Beck
OBJECTIVE: To evaluate the safety and explore the efficacy of use of ultra-rapid lispro (URLi, Lyumjev) insulin in the Tandem t:slim X2 insulin pump with Control-IQ 1.5 technology in children, teens and adults living with type 1 diabetes (T1D). METHODS: At 14 U.S. diabetes centers, youth and adults with T1D completed a 16-day lead-in period using lispro in a t:slim X2 insulin pump with Control-IQ 1.5 technology followed by a 13-week period in which URLi insulin was used in the pump...
May 2, 2024: Diabetes Technology & Therapeutics